IRADIMED CEO’s trust sells 7,500 shares
IRADIMED CORP insider Roger E. Susi, CEO, President and Chairman, reported that the Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of common stock in open-market transactions on April 6–7.
Rhea-AI Filing Summary
IRADIMED CORP insider Roger E. Susi, CEO, President and Chairman, reported that the Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of common stock in open-market transactions on April 6–7. Reported sale prices ranged from $94.36 to $96.78 per share, and the filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 5, 2025.
Following these sales, the Phillip Susi 2008 Dynasty Trust holds 2,217,500 shares. The filing also reports indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, and states that Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares
Net Sell
7 txns
Insider
Susi Roger E.
Role
CEO, President, Chairman
Sold
7,500 shs ($717K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,518 | $94.36 | $143K |
| Sale | Common Stock | 982 | $95.58 | $94K |
| Sale | Common Stock | 1,357 | $95.21 | $129K |
| Sale | Common Stock | 3,074 | $96.24 | $296K |
| Sale | Common Stock | 569 | $96.78 | $55K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,217,500 shares (Indirect, By Phillip Susi 2008 Dynasty Trust);
Common Stock — 162,950 shares (Indirect, By Roger E. Susi Revocable Trust);
Common Stock — 2,062,500 shares (Indirect, By Matthew Susi 2008 Dynasty Trust)
Footnotes (7)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $94.54 to $95.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $95.61 to $96.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $96.61 to $97.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $94.15 to $95.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $95.17 to $95.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 7,500 shares
Lowest reported sale price: $94.36 per share
Highest reported sale price: $96.78 per share
+3 more
6 metrics
Shares sold
7,500 shares
Open-market sales on April 6–7, 2026
Lowest reported sale price
$94.36 per share
Common stock sale by trust
Highest reported sale price
$96.78 per share
Common stock sale by trust
Shares held by Phillip Susi 2008 Dynasty Trust
2,217,500 shares
Indirect holding after reported sales
Shares held by Roger E. Susi Revocable Trust
162,950 shares
Indirect holding as of April 6, 2026
Shares held by Matthew Susi 2008 Dynasty Trust
2,062,500 shares
Indirect holding as of April 6, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Section 16, Dynasty Trust, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price"
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Dynasty Trust financial
"By Phillip Susi 2008 Dynasty Trust"
Revocable Trust financial
"By Roger E. Susi Revocable Trust"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did IRADIMED (IRMD) report for Roger E. Susi?
IRADIMED reported that a trust associated with CEO Roger E. Susi sold 7,500 common shares. The Phillip Susi 2008 Dynasty Trust executed open-market sales on April 6–7 at reported prices between $94.36 and $96.78 per share, under a pre-established Rule 10b5-1 trading plan.
Were the IRADIMED (IRMD) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan. That plan was adopted by the reporting person on November 5, 2025, indicating that the transactions were pre-arranged rather than decided at the time of execution.
AI-generated analysis. How Rhea-AI works. Not financial advice.
